Another paper from the PICOBOO randomized trial, evaluating second boosters after mRNA priming.
A trio of Novavax preprints, showing 1) remarkable durability 6 months, 2) cross protection against newer variants, and 3) low reactogenicity (side effects), supporting NVX as an excellent booster platform.
“A trio of Novavax preprints, showing 1) remarkable durability >6 months, 2) cross protection against newer variants, and 3) low reactogenicity (side effects), supporting NVX as an excellent booster platform.”